Trinity Biotech (TRIB) Fundamental Analysis: Revenue, Earnings & Valuation

0.17 / 10

Underperform

Fundamentals are weak, rating Underperform with a 0.2/10 score. ROA sits at –14.55% and profit margins are deeply negative, while EBIT margin is also poor. Cash‑flow to revenue is –24.96%, indicating significant risk.

Analysis Checks(4/6)

ROA (%)

Value-14.55

Score2/3

Weight-46.00%

1M Return0.64%

Net cash flow from operating activities / Operating revenue (%)

Value-24.96

Score0/3

Weight276.36%

1M Return-6.63%

Annualized net profit margin on total assets (%)

Value-29.10

Score2/3

Weight-46.00%

1M Return0.64%

EBIT / Total operating revenue (%)

Value-54.52

Score3/3

Weight-117.41%

1M Return1.53%

Net profit / Total operating revenue (%)

Value-80.23

Score3/3

Weight-104.97%

1M Return1.41%

Net profit / Total profit (%)

Value102.07

Score1/3

Weight138.02%

1M Return-2.39%

Is TRIB fundamentally strong?

TRIB scores 0.17/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -73.83% net margin, -0.31 P/E ratio, -0.23 P/B ratio, and 39.76% earnings growth, these metrics solidify its Underperform investment rating.